Cardiac Marker Testing Market: Benefits and Market Potential in Healthcare

In recent years, the field of healthcare has experienced significant growth with many superior technological developments and has achieved several milestones through extensive research. From the development of new tools, equipment, and tests to their successful delivery to the right patient in the right way, the healthcare sector has achieved remarkable progress in terms of patient care and outcomes. Just like these advancements, cardiac marker testing is one of the significant developments in the healthcare sector. In this blog, we will explore the benefits of cardiac markers and their market potential.

What Is Cardiac Marker Testing?

This test is used to measure the levels of cardiac biomarkers in the blood to diagnose patients with chest pain and expected acute coronary syndrome (ACS). Cardiac marker Testing helps physicians to analyze acute coronary syndrome (ACS), and manage high-risk patients with acute heart failure, pulmonary embolism, and other disease states. Creatine kinase-MB [CK-MB] fraction, soluble CD40 ligand [sCD40L], myoglobin and cardiac troponins, C-reactive protein [CRP], and homocysteine are all used to signify acute myocardial infarction, commonly known as a heart attack.

The Incredible Potential of the Market

According to Polaris Market Research, the global cardiac marker testing market was valued at USD 4.42 billion in 2022 and is expected to obtain USD 9.73 billion at a CAGR of 8.43% during the forecast period.

Growing prevalence of acute coronary syndrome, high technological developments in cardiac biomarkers, specificity in detecting cardiac disorders, and rise in demand for point-of-care cardiac testing kits are among the key aspects driving the cardiac marker testing market growth. The growing popularity of these test kits, owing to the quick diagnosis and results obtained, which reduces the diagnostic time involved and expedites the overall treatment process, is anticipated to boost the market growth. Also, the growing emphasis on developing new and more updated devices and test kits among key players is projected to propel the industry expansion.

To Get Insights on the Cardiac Marker Testing Market:  Request for a Sample Report

Which Type of Biomarker Is Commonly Utilized in Clinical Practice?

“Troponin I and T are cardiac regulatory proteins are cardiac regulatory proteins”

Troponin I and T are used in clinical practice to assess cardiac health and diagnose conditions such as myocardial infarction, also known as heart attack and other types of heart damage. These proteins are highly sensitive and help in detecting the protein rapidly as compared to traditional troponin tests, which is majorly driving the cardiac marker testing market growth.

Creatine Kinase-MB (CK-MB), Myoglobin, High-Sensitivity C-Reactive Protein, and Natriuretic Peptide are among other key cardiac markers. The natriuretic peptide category is also widely used in the detection of heart damage and stress owing to the increasing awareness of the availability of these tests among patients, particularly in developed nations such as the United States, France, and Germany.

Wrap Up

North America witnessed the largest cardiac marker testing market share and is anticipated to continue its dominance over the forecast period. This growth can be attributed to the presence of well-established and developed healthcare infrastructure and the rising usage of cardiac biomarkers as a crucial tool for the diagnosis of many illnesses. As technology advances, cardiac marker testing will play an ever greater role in improving patient outcomes and determining the future of cardiovascular care.

---